IQVIA Real World Solutions, La Defense, France.
IQVIA Real World Solutions, Gurugram, Haryana, India.
Pharmacoepidemiol Drug Saf. 2021 Sep;30(9):1143-1152. doi: 10.1002/pds.5301. Epub 2021 Jun 24.
This review aims to describe the sampling methodology used in studies assessing effectiveness of risk minimisation measures (RMMs) in the European Union.
The European Union electronic Register of Post-Authorization Studies (EU PAS Register) was searched to identify studies that assessed the effectiveness of RMMs and recruited a target population of healthcare professionals (HCPs), sites or patients. Studies with both protocol and report were included and data was extracted from these documents to describe study characteristics and variables involved in the sampling methodology.
Out of 1092 studies finalised between June 2017 and May 2019, 17 studies were eligible for review. Thirteen were surveys, three chart reviews and one combined both methodologies. All the 17 studies recruited HCPs/sites and 8 of them also recruited patients. The most common rationale for country sampling was market uptake (10/17), while for HCP/site sampling, it was representativeness of the prescribing practices (14/17). Only a minority of the studies (4/17) provided supporting evidence to inform this theoretical framework. HCP/site sampling frames were mainly network of physicians (5/17) or HCP databases (5/17), with only one study providing a detailed description of the sampling frame. HCPs were selected mainly using probabilistic sampling (10/17) and patients using non-probabilistic sampling (6/8). Only a few studies compared participating with non-participating HCPs/sites (5/17) and patients (3/8). Eight studies reported that their results were generalisable.
Overall, the study documents provided insufficient details to understand the rationale behind the sampling decisions. More standardisation and guidance in reporting the sampling strategy and operational considerations applicable to these types of studies would support transparency and facilitate the evaluation of representativeness of the study results.
本综述旨在描述在欧盟评估风险最小化措施(RMM)有效性的研究中使用的抽样方法。
检索了欧盟药品上市后研究电子注册库(EU PAS 注册库),以确定评估 RMM 有效性并招募医疗保健专业人员(HCP)、地点或患者为目标人群的研究。纳入既有方案又有报告的研究,并从这些文件中提取数据,以描述研究特征和抽样方法中涉及的变量。
在 2017 年 6 月至 2019 年 5 月期间完成的 1092 项研究中,有 17 项研究符合审查条件。其中 13 项为调查研究,3 项为图表回顾,1 项同时采用了这两种方法。这 17 项研究均招募了 HCP/地点,其中 8 项研究还招募了患者。进行国家抽样的最常见理由是市场占有率(10/17),而进行 HCP/地点抽样的最常见理由是处方实践的代表性(14/17)。只有少数研究(4/17)提供了支持性证据来为这一理论框架提供信息。HCP/地点抽样框架主要是医生网络(5/17)或 HCP 数据库(5/17),只有一项研究详细描述了抽样框架。HCP 主要通过概率抽样(10/17)选择,患者主要通过非概率抽样(6/8)选择。只有少数研究比较了参与和不参与的 HCP/地点(5/17)和患者(3/8)。有 8 项研究报告称其结果具有普遍性。
总体而言,研究文件提供的细节不足以了解抽样决策背后的基本原理。在报告抽样策略和适用于这些类型研究的操作考虑因素方面,增加更多的标准化和指导,将有助于提高透明度,并促进对研究结果代表性的评估。